Manfredi Mark 4
4 · Ikena Oncology, Inc. · Filed Feb 4, 2022
Insider Transaction Report
Form 4
Manfredi Mark
DirectorPresident & CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-02-03+238,900→ 238,900 totalExercise: $9.76Exp: 2032-02-03→ Common Stock (238,900 underlying)
Footnotes (1)
- [F1]25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.